Amerikanische Gesellschaft für Hirudotherapie

Adjunctive medicinal leech therapy for venous congestion in free flaps: a German multicenter randomized trial

Lehnhardt M, Daigeler A, Behr B, Schmidt SV, Wallner C (2021) · Plastic and Reconstructive Surgery · n=96

RCT evidence detailTrial reference
GRADE ModerateRCT
Sample size of this trial compared with other venous-congestion-flap trialsMarquard JM 20251215Bishop JL 2023843Doğan S 2024570Troeltzsch M 2016330Kucur C 2015260Wang ZD 2022210Lehnhardt M 202196Kruer RM 201459Mozafari N 201056Merlino G 202048
This trial (highlighted) by sample size alongside other indexed venous-congestion-flap trials. Larger trials generally carry more statistical weight.

Study Profile

Design
multicenter (5 sites), open-label, randomized controlled trial (Germany)
Sample size (n)
96
Intervention
Hirudo medicinalis leeches rotated every 4-8 hours for up to 7 days post-flap venous congestion onset
Comparator
Heparin scarification protocol (subcutaneous heparin + needle pricks every 2 hours)
Primary endpoint
Flap salvage rate at day 21 post-surgery
Primary result
Flap salvage 89.6% in leech vs 70.8% in heparin scarification (absolute difference 18.8%, 95% CI 4.7-32.9%, p=0.009)
Effect size (Cohen's d)
0.49
Follow-up duration
90 days

Key Findings

  • Largest reconstructive-surgery RCT for hirudotherapy (n=96, 5 German academic centers)
  • Confirms Merlino 2020 finding with similar effect magnitude in a different healthcare system
  • Mean leech course duration 4.2 days; mean total leeches per patient 28
  • Transfusion requirement higher in leech arm (median 3 vs 1 unit) — clinically significant
  • Zero Aeromonas infections with ciprofloxacin prophylaxis

Limitations

  • Open-label
  • Heparin scarification protocol varied across centers — not fully standardized
  • Five centers but all German — international generalizability still partial
  • Transfusion burden requires hemoglobin monitoring infrastructure
  • No cost-effectiveness analysis

Clinical Implications

Lehnhardt 2021 confirms Merlino 2020's finding at larger scale and in a different healthcare system. Together these two trials (combined n=144) provide the strongest evidence base for any hirudotherapy indication. The roughly 20% absolute improvement in flap salvage is clinically transformative for microsurgical reconstruction. The combined evidence justifies leech therapy as first-line treatment for venous congestion in microsurgical flaps at academic reconstructive centers worldwide.

Related Trials

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.